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ABSTRACT 
Mozambique is one of the high burden tuberculosis (TB) and human immunodeficiency virus 
(HIV) countries with a prevalence of HIV infection in adults of 11.5% and an estimated TB 
prevalence of 559 per 100 000 population. Fifty six percent of the TB patients in 
Mozambique are estimated to be HIV positive. TB control strategies might significantly be 
affected by differences in virulence, epidemiologic characteristics and epidemiology of 
particular strains of the Mycobacterium tuberculosis complex. Molecular epidemiology 
studies allow the identification of circulating strain types, understanding of transmission 
dynamics, as well as investigations of the evolution of the M. tuberculosis complex.  
The studies included in this thesis described the molecular epidemiology of M. tuberculosis 
complex in Mozambique, identified predominant genotypes responsible for TB transmission 
and prevalence and investigated the association between predominant spoligotypes and HIV 
sero-status. The prevalence and transmission of the Beijing genotype in Mozambique was 
also evaluated. With the aim to explore the public health risk for bovine TB, isolates from 
two sites were investigated, Maputo (tuberculous lymphadenitis or TBLN cases) and Govuro 
district (TBLN and pulmonary cases), the last site, Govuro, with known high prevalence of 
bovine TB in cattle (39.6%). Furthermore, a phylogenetic phylogeographic snapshot of 
worldwide M. tuberculosis complex diversity was created based on the classification of the 
Multiple-locus variable-number tandem repeat analysis (MLVA).  
For the first time, the genetic diversity of circulating M. tuberculosis complex strains in 
Mozambique was described. It was found that the TB epidemic in Mozambique was caused 
by a wide diversity of spoligotypes with predominance of the Latin-American Mediterranean 
(LAM, n=165 or 37%); East African-Indian (EAI, n=132 or 29.7%); the evolutionary recent 
T clade (n=52 or 11.6%) and the globally-emerging Beijing clone (n=31 or 7%). The 
predominant lineages were also common in neighboring countries, indicating TB 
transmission by migration from one country to another.  
The Beijing lineage, distributed worldwide and responsible for large epidemics was found to 
be particularly common in the Southern region of Mozambique, especially in Maputo City 
(17%) and associated with HIV infection (p=0.023). By combined use of region of difference 
(RD) analysis and spacer oligonucleotide typing (spoligotyping), a distinct group of four 
isolates had deletion of RD150, a signature of the “sublineage 7” recently emerging in South 
Africa. The same group was very similar to the South African “sublineage 7” by Restriction 
Fragment Length Polymorphism (RFLP) and Mycobacterial Interspersed Repetitive Units–
Variable-Number Tandem Repeat (MIRU-VNTR), suggesting that this sublineage could have 
been recently introduced in Mozambique from South Africa. 
No M. bovis was found in TBLN cases from Maputo. It was demonstrated that TBLN in 
Maputo was caused by a variety of M. tuberculosis genotypes, similar to the ones causing 
pulmonary TB, suggesting that in Maputo, cases of TBLN arise from the same source as 
pulmonary TB, rather than from an external zoonotic source. 
For the first time, evidence of the occurrence of M. bovis in humans in Mozambique was 
revealed. In a study presently being conducted in the district of Govuro, among six M. 
tuberculosis complex isolates, one was M. bovis. Nevertheless, further research is needed on 
cases of abdominal TB and other forms of extrapulmonary TB, in Govuro and in other 
pastoral areas, where the prevalence of bovine TB in cattle is known to be high, in order to 
have a better answer about the public health importance of this zoonotic disease in 
Mozambique.  
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1 INTRODUCTION 
1.1 GLOBAL BURDEN OF TUBERCULOSIS  
Tuberculosis (TB) stands as a major global health problem, ranking as the second highest 
cause of death from an infectious disease globally, after the human immunodeﬁciency virus 
(HIV) (1). The World Health Organization (WHO) estimates that 9.0 million people 
developed TB in 2013, of whom, 13% were HIV positive individuals. Among the incident 
cases, 56% were from the South-East Asian and Western Paciﬁc Regions and one quarter 
were from Africa. The African continent accounts for the highest rates of cases and deaths 
relative to population (1).  
Figure 1 shows the estimated TB incidence for the top-ten countries in 2013. 
In 2013, WHO estimates that 1.5 million deaths occurred due to TB (360 000 of whom were 
HIV positive). Among these deaths 210 000 were from multidrug resistance (MDR) patients, 
representing 43.75% of the total incident cases of MDR-TB.   
 
Figure 1. Estimated WHO TB incidence rate per 100 000 population: top-ten countries, 2013. Reproduced with 
permission from the World Health Organization (1). 
In 2014, a post 2015 TB strategy was announced by the World Health Assembly, with the 
goal of ending the global TB epidemic with targets to reduce TB deaths by 95% and reduce 
incident cases by 90% until 2035 (2). 
TB is a disease of poverty (3,4). A lack of basic health services, malnutrition, social 
disruption, tobacco consumption and inadequate living conditions all contribute to the 
dissemination of TB and its impact in the community. HIV infection and Acquired Immune 
Deficiency Syndrome (AIDS) amongst others are the strongest risk factor for TB (5). The 
observed increase in TB incidence in sub-Saharan Africa may have resulted from several of 
these factors. 
 
1.1.1 Drug Resistant TB   
The ability of a bacterial cell to survive the presence of a drug at a concentration that 
normally kills or inhibits growth is called resistance. Drug resistant TB is a particular 
problem because of the prolonged therapy of at least six months that makes patient 
compliance very difficult, frequently creating drug resistant Mycobacterium tuberculosis 
complex strains. Other factors that contribute to the development of resistance are the 
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inadequate use of antimicrobials, low compliance and completion of treatments, together with 
poor TB control programs and lack of access to drugs (6). 
The emergence of drug resistance is a serious threat to global efforts to control TB (1,6–8).  
Particular terminologies are used to define resistance in TB (9): 
- Mono-resistance, defined as resistance to one first-line anti-TB drug only; 
- Polydrug resistance, defined as resistance to more than one first-line anti-TB drug 
(other than both isoniazid and rifampicin);  
- MDR, defined as resistance to at least both isoniazid and rifampicin; 
- Extensively drug resistant (XDR), defined as a MDR strain which is also resistant to 
one of the three second line injectable drug (capreomycin, kanamycin or amikacin) 
and any fluoroquinolone; 
- Rifampicin resistance, defined as resistance to rifampicin based on phenotypic or 
genotypic methods, with or without resistance to other anti-TB drugs. It includes any 
resistance to rifampicin, whether monoresistance, MDR, polydrug resistance or XDR. 
 
Recently the term totally drug-resistant TB, although not clearly defined, has been used to 
define a strain resistant to a wider range of drugs than strains classified as XDR-TB (10). 
These types of strains have been reported in Italy (11), Iran (12), India (13,14) and South 
Africa (15). 
Globally, 3.5% of new and 20.5% of previously treated TB cases were estimated to have had 
MDR-TB in 2013 and 9.0% of patients with MDR-TB had XDR-TB (1). In 2013, 55% of 
reported TB patients estimated to have MDR-TB were not detected (1). 
To address the MDR-TB epidemic, the WHO considers five priority actions needed: 1) high-
quality treatment of drug-susceptible TB to prevent MDR-TB; 2) expansion of rapid testing 
and detection of MDR-TB cases; 3) prompt access to quality care; 4) infection control; and 5) 
increased political commitment, including adequate funding for current interventions as well 
as research to develop new diagnostics, drugs and treatment regimens (1). 
 
1.1.2 TB and HIV in Africa 
The emergence of HIV had a unique impact on the epidemiology of infectious diseases in 
general and particularly on TB (16). Individuals with latent M. tuberculosis infection who 
contract HIV are at risk of developing active TB at a rate of 7 to 10% per year, compared to 
approximately 8% per lifetime for HIV negative individuals (17,18). Thus, the dissemination 
of the HIV infection has contributed to the expansion of TB, which is the main cause of 
mortality among HIV patients. 
In Africa, the proportion of TB cases co-infected with HIV is the highest (1). WHO estimated 
that in 2013, 34% of TB cases were co-infected with HIV in the continent, accounting for 
78% of TB cases among people living with HIV worldwide (Figure 2). 
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Figure 2. WHO estimated HIV prevalence in new and relapse TB cases, 2013. Reproduced with permission 
from the World Health Organization (1). 
The emergence of HIV has not only increased TB incidence and TB associated mortality but 
it has also made the diagnostics of TB more problematic (16). Diagnosis of active TB disease 
in HIV-infected people is difficult, because patients with HIV associated TB are 
paucibacillary (i.e. have fewer bacilli in their sputum) when compared to HIV uninfected 
patients with pulmonary TB (19). Therefore, the WHO recommends the use of recent new 
diagnostic technologies, such as the GeneXpert, in order to increase case detection in that 
particular group and among MDR-TB suspects (20). 
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1.2 MOZAMBIQUE, THE COUNTRY 
The Republic of Mozambique has a population of 25,727,911 inhabitants (21), it is located in 
Southern Africa and divided per 11 provinces and 128 districts. The country suffered almost 
five centuries of Portuguese colonization, a massive migration of skilled workers after the 
independence in 1975 and a terrible civil war that ended in 1990 where half of public health 
facilities and schools were destroyed.  
Mozambique is now experiencing a period of political and economic transition, with a newly 
elected president and the expected promotion of natural gas projects that are expected to 
modify the country’s economic and social scenery (22).  
The economic situation of Mozambique has improved over the years, in 2014 the Gross 
Domestic Product (GDP) grew by 7.6% and growth is likely to remain strong, at 7.5% and 
8.1% in 2015 and 2016, respectively, enhanced by the construction, transport and 
communications sectors (22). In Mozambique, the majority of the population is greatly 
dependent on natural resources for their livings and the primary sector plays a critical role in 
the country’s economy. In addition, the country is rich with a variety of mineral resources, 
especially gas, coal, oil, heavy-sand deposits, gold, copper, titanium, graphite and other 
minerals in significant quantities (22). 
While the economy has expanded strongly, its effect on poverty reduction has been minimal. 
The majority of Mozambicans (55%) still live below the consumption poverty line of USD 
0.6 a day (22). The life expectancy is 53 years of age and access to health services remains 
low (21).  
Inadequate financing, shortage of health professionals and essential medicines, all these 
historical, social and economic factors influence the present extreme poverty and health 
inadequacy in Mozambique (23,24).  
 
1.2.1 TB and HIV in Mozambique 
TB represents one of the principal causes of morbidity and mortality in Mozambique, 
affecting the main vulnerable groups, including young adults, children and people living with 
HIV/AIDS. This situation makes the early diagnosis and management of TB and MDR-TB 
cases a priority for the National TB Control Program (25). Since 1993, Mozambique stands 
on the list of the 22 high burden TB countries, where the prevalence rate is of 559 per 
100,000 population (1).  
In Mozambique, all Health Units have the capacity to perform Institutional DOTS (Directly 
Observed Treatment, Short-course), implying 100% coverage. However, many of the health 
facilities in the country, particularly at peripheral level, still have weaknesses, that can be 
observed in the number of screening and patients diagnosed. The major obstacle is the lack of 
human resources to perform preventive and curative care tasks (25). 
The TB epidemiological distribution in the country varies from region to region. The Central 
and South Regions of the country have the highest burden of disease, with 41.6% and 38.3% 
of total notified cases, respectively (23).  
MDR-TB remains one of the major challenges for the National TB Control Program, with a 
prevalence of 3.5% in new cases and 11% in previously-treated patients (26). 
Presently Mozambique has 337 laboratories performing smear microscopy for TB diagnosis 
and three TB Reference Laboratories, located in Maputo, Beira and Nampula. All of the 
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reference laboratories are fully operational, performing cultures on solid and liquid media, 
rapid speciation and drug susceptibility testing (DST) of the M. tuberculosis complex, the 
first one also performing rapid detection of MDR-TB using Line Probe Assay (LPA). The 
National TB Reference Laboratory, located in the capital Maputo, recently achieved the ISO 
15189 accreditation for fluorescent microscopy and cultures on solid and liquid media, 
representing the first clinical laboratory reaching international accreditation in Mozambique, 
an enormous achievement for patient care. 
Recent molecular diagnostic tools as the GeneXpert are currently being implemented in the 
country, focusing on MDR-TB detection and diagnosing TB in HIV co-infected patients. At 
present 36 laboratories have the capacity to perform GeneXpert. 
Regarding HIV, the civil war had two opposing effects, the first in protecting the country 
from the spread of HIV as it influenced population movements (27) and at the same time 
facilitating the spread of HIV by eroding traditional norms, destroying the health care 
infrastructure and influencing labor migration to and from neighboring countries with high 
HIV and TB prevalences (28). The actual prevalence of HIV in adults (15-49 years) in the 
country is 11.5% and more women are infected (13.1%) compared to men (9.2%) (29).  
The prevalence of HIV among TB patients decreased from 58% in 2012 to 56% in 2013. In 
2013, 91% of TB patients knew their HIV status (1). 
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1.3 THE IMPORTANCE OF STUDIES ON MOLECULAR EPIDEMIOLOGY OF 
TB 
Molecular epidemiological studies of TB, based on molecular techniques enabled studies to 
address important epidemiological questions, such as outbreak investigations (30–34), 
describing transmission dynamics (35–38), estimates of recent-versus-reactivation disease 
and the extent of exogenous reinfection (39–41). Furthermore, molecular epidemiological 
studies have also enabled the understanding of spatiotemporal transmission and evolutionary 
dynamics (42–46) and generate evidence that different strains of the M. tuberculosis complex 
from distinct phylogenetic lineages may differ in virulence, pathogenesis, and epidemiologic 
characteristics, influencing TB control and vaccine development strategies (47).  
Below are summarized some applications of molecular techniques in TB epidemiology 
described by Mathema and colleagues (47):  
- Study of the M. tuberculosis complex transmission dynamics (outbreak, transmission, 
chains of transmission, risk factors and groups at risk of M. tuberculosis complex 
infection). 
- Discriminating recurrent TB due to exogenous reinfection and reactivation. 
- Detection of laboratory error/cross-contamination. 
- Determination of geographic spread of strains. 
- Monitoring transmission of drug-resistant strains. 
- Investigation of the evolution of drug-resistant TB within and between patients. 
- Detection of mixed infections among TB patients. 
- Sampling of strain types for further studies. 
- Evaluation of TB control programs (level of clustering). 
- Identification of strain-specific transmission/infection rates. 
- Identification of predominant strain types (clonal strains) in study populations. 
- Identification of hypervirulent strains in populations. 
- Investigation of the evolution of the M. tuberculosis complex. 
 
  
  7 
1.4 THE MYCOBACTERIUM TUBERCULOSIS COMPLEX 
TB is caused by bacteria belonging to the M. tuberculosis complex, which consists of highly 
related slow growing, acid-fast, aerobic, non-spore forming, non-motile bacteria. They form 
slightly curved or straight rods which may branch (0.2 to 0.6 µm by 1.0 to 10 μm) (48).  
The M. tuberculosis complex comprises seven members, M. tuberculosis, M. africanum, 
M. canettii where the natural host are humans and M. bovis, M. caprae, M. microti and 
M. pinnipedii which usually have animals as their natural hosts. In addition, rare M. 
tuberculosis complex variants, standing within the M. tuberculosis complex are not yet 
completely described; the M. suricattae, M. mungi and the Dassie bacillus. 
Although the mycobacterial species of the M. tuberculosis complex are highly similar to each 
other on Deoxyribonucleic Acid (DNA) level, M. tuberculosis complex members differ 
widely in terms of host tropism, phenotype and pathogenicity (42,49,50). Detection of the 
different species within the complex has mainly been based on the analysis of phenotypic 
characteristics such as acid-fast microscopy, colony morphology, growth rate and 
biochemical tests. Genotyping methods have currently made epidemiological studies and 
rapid species discrimination more promising, enlarging our understanding of phylogenetic 
relations and evolutionary origin of the members of the M. tuberculosis complex. 
 
1.4.1 Mycobacterium tuberculosis 
M. tuberculosis is the principal agent of TB in humans, first described by Robert Koch in 
1882 (51). Regarding the origin of the M. tuberculosis complex strains, it was previously 
presumed that M. tuberculosis had evolved from M. bovis by specific adaptation of an animal 
pathogen to the human host (52–54). However, genomic analysis has shown that M. bovis has 
a smaller genome, suggesting that it is evolutionary younger (42).  
Phenotypically, M. tuberculosis can be identified using analysis such as nitrate reductase, 
production of niacin, resistance to thiophene-2-carboxylic acid hydrazide (TCH) and 
sensitivity to pyrazinamidase (55,56). Genotypically, by Spacer Oligonucleotide Typing 
(spoligotyping), M. tuberculosis has been classified into different phylogenetic lineages (57). 
 
1.4.2 Mycobacterium bovis and Mycobacterium bovis BCG  
Bovine TB, caused by M. bovis is the main zoonotic disease caused by mycobacteria, 
affecting cattle, other domesticated animals and certain free or captive wildlife species. The 
disease is spread to humans, typically by ingestion of unpasteurized milk or contaminated 
meat, causing extrapulmonary  TB, but can also be transmitted by inhalation of aerosols 
causing pulmonary TB (58,59).  
TB caused by M. bovis and TB caused by M. tuberculosis cannot be distinguished clinically, 
radiographically, or pathologically in individual patients (60). Thus, the identification of these 
causative agents can only be through mycobacterial culture and subsequent use of 
biochemical or molecular methods (61). However, containment facilities to identify the 
causative agent of TB are largely absent in low income countries (61) . 
In high income countries, zoonotic TB accounted for a relevant proportion of the TB cases 
until the introduction of regular milk pasteurization programs (61). In our days, bovine TB is 
well controlled or eliminated, and zoonotic TB cases are rarely seen; however, reservoirs in 
wildlife can make complete eradication challenging (62,63). 
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In Africa, the situation is somehow more critical, as bovine TB is an economical and public 
health threat in low income countries (58). In most African countries, effective control of 
bovine TB is largely absent, including regular milk pasteurization and slaughterhouse meat 
inspection (58,59). Additionally, the presence of multiple risk factors such as human 
behaviour and HIV infection (58,59,62) makes the situation even worse. The reported median 
proportion of bovine TB in Africa is 2.8% (range 0%–37.7%) of human TB cases (58). 
Control policies have not been enforced due to cost implications, lack of capacity and 
infrastructure limitations (58,59). 
There is also a non-virulent strain of M. bovis called Bacillus Calmette Guerin (BCG), which 
has its origin from a virulent M. bovis strain (64). Calmette and Guerin performed 230 in 
vitro passages of M. bovis until the organism lost its virulence. While this strain has been 
used worldwide as a live attenuated vaccine to immunize people against TB, with highly 
variable efficacy (65), it may cause disease in humans. In many high TB incident countries, 
the BCG vaccination is mandatory and free of charge, given on the first three days after birth, 
showing protection in children against more serious forms of TB (66,67), although in adults, 
protection varies from 0 to 80% (68). 
 
1.4.3 Mycobacterium africanum 
M. africanum was first described in 1968 in a Senegalese patient (69), after that it was found 
almost exclusively in West Africa. The prevalence of M. africanum varies from 5,3% in the 
Ivory Coast (70), 47,1% Guinea-Bissau (71) and 67,7% in Uganda (72). 
M. africanum is phenotypically heterogeneous, with characteristics common to both M. 
tuberculosis and M. bovis. Based on their geographic origin and biochemical characteristics, 
two subgroups of M. africanum have been described, in western Africa (subtype I) and 
eastern Africa (subtype II) (73). 
 
1.4.4 Mycobacterium canettii 
M. canettii, a rare variant of the M. tuberculosis complex with smooth colony morphology 
was first isolated from a Somali-born patient in 1969 by Canetti (74). M. canettii differs from 
the other M. tuberculosis complex strains by having large amounts of lipooligosaccharides on 
the cell wall (75). The smooth and glossy colonies produced are highly exceptional for this 
species. This smooth phenotype is however unstable and can switch to a rough colony 
morphology (74). 
 
1.4.5 Mycobacterium microti 
M. microti, is the causative agent of TB in voles, wood mice, and shrews and can also cause 
disease in a limited number of other mammalian species.  
It was described for the first time by Wells in 1946, in voles (Microtus agrestis) from Great 
Britain (76). In humans, it was first reported in 1998 in immunocompromised patients (77), 
although human to human transmission of M. microti infection seems to be rare (78).  
Based on biochemical properties, this bacterium is difficult to distinguish from M. 
tuberculosis, M. africanum, or M. bovis, but M. microti strains display characteristic Insertion 
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sequence (IS)6110 Restriction Fragment Length Polymorphism (RFLP) banding patterns and 
spoligotypes, distinct from other M. tuberculosis complex strains (77).  
 
1.4.6 Mycobacterium pinnipedii 
In 1993, it was reported for the first time that isolates from seals captured on the coast of 
Argentina had a characteristic IS6110 RFLP pattern (79). This seal bacillus was later 
designated M. pinnipedii and appeared to have a unique position in the M. tuberculosis 
complex (79). Later on, reports have described M. pinnipedii infections in various marine 
mammals (80–82). 
Transmission of M. pinnipedii to humans has been reported in individuals who are in close 
contact with marine mammals (82,83).  
M. pinnipedii isolates present a distinct spoligotype pattern when compared to other members 
of the M. tuberculosis complex (79).  
 
1.4.7 Mycobacterium caprae 
M. caprae was first isolated from goats in Spain (84), but has since been found in other 
animals in Europe, such as cattle (85–87), pigs (88), red deer (88) and wild boars (86). Its 
isolation from humans has also been described (86,89).  
Based on biochemical tests, results are similar to M. bovis and M. bovis BCG. By 
spoligotyping, M. caprae species form a homogeneous cluster easily recognizable by the 
absence of spacers 1,3-16, 30-33 and 39-43. The lack of spacers 39-43 has also been 
described in M. bovis and M. microti (84,90). 
 
1.4.8 Novel variants of the M. tuberculosis complex  
The novel M. mungi, was identified as the causative agent of TB in banded mongooses 
(Mungos mungo), in Botswana (91). M. mungi was characterizes as highly virulent, causing 
high numbers of deaths in a short period of time (2–3 months from clinical presentation to 
death), apparently through environmental transmission (nonrespiratory route) (91).  
The Dassie bacillus, the causative agent of TB in the dassie (Procavia capensis), is 
considered an infrequent variant of the M. tuberculosis complex characterized as being 
similar to M. microti, based on morphology and growth requirements (92), although, they 
differ in growth preferences and bacillary morphology under microscopy. In terms of 
pathogenicity, the Dassie bacillus was reported to have a very low level of virulence in 
rabbits and guinea pigs (93). Genome comparison of nine regions of difference (RD) shows 
that five are shared with M. microti (RDs 3, 7, 8, 9, and 10). Although the Dassie bacillus 
does not share the other documented deletions in M. microti (RD1mic, RD5mic, MID1, MID2, 
and MID3) (94). 
The M. orygis or Oryx bacilli was identified to be the causative agent of TB in oryxes and 
gazelles (95), deer, antelope and waterbucks (50), although their exact host range remains 
uncertain. Combined findings based on Single nucleotide polymorphisms (SNP), RD, 
spoligotyping and 24-locus Mycobacterial Interspersed Repetitive Units–Variable-Number 
Tandem Repeat (MIRU-VNTR) analysis, placed M. orygis at a distinct phylogenetic position 
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between the Dassie bacillus and M. microti. It was proposed by Ingen and colleagues that M. 
orygis was attributed a subspecies status (96). 
M. suricattae, closely related to the Dassie bacillus was first isolated in meerkats from South 
Africa, it was proposed as a novel member of the M. tuberculosis complex (97). The deletion 
of the direct-repeat region spacers, i.e. no amplification of any spacer by spoligotyping, 
distinguishes this strain from all other M. tuberculosis complex members (97).  
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1.5 LABORATORY DIAGNOSIS OF TB 
The bacteriological conﬁrmation of TB and the determination of drug susceptibility are 
essential to ensure that a patient is correctly diagnosed with TB and started on the most 
eﬀective treatment regimen (1). In 2013, among all new cases of TB, only 58% were 
bacteriologically confirmed worldwide (1). 
 
1.5.1 Identification of the M. tuberculosis complex 
1.5.1.1 Microscopy 
Smear microscopy, based on the Ziehl-Neelsen (ZN) stain, is often the only diagnostic tool 
available in resource-limited settings for detection and diagnosis of TB. The purpose of this 
approach is to ensure detection of most infectious cases with minimal cost, which is essential 
for low income countries. However, the sensitivity is low when the bacterial load is less than 
10,000 organisms/ml sputum sample (98). The sensitivity of smear microscopy is further 
reduced in diagnosing extrapulmonary  TB, pediatric TB and TB in patients co-infected with 
HIV (99–101), based on the paucibacillary nature of TB disease in these patients. In addition 
it cannot distinguish M. tuberculosis complex from other mycobacteria. 
Fluorescence microscopy, based on auramine O fluorescence acid fast stain, is 10% more 
sensitive than ZN staining (102). This method uses a lower power objectives lens (25x, while 
the ZN uses 100x), that makes the reading faster. The light-emitting diodes (LED) 
microscopy now being used for fluorescent microscopy, is less expensive and there is no 
need of a dark room, which means the same infrastructure as the one for conventional ZN 
staining, making the implementation much easier.    
In order to improve the diagnostics by smear microscopy, the WHO have recommended the 
gradual substitution of the ZN microscopy to fluorescent microscopy (102). 
 
1.5.1.2 Culture 
Culture, considered the most accurate test due to high sensitivity and specificity, is labor-
intensive and slow. Clinical laboratories hold cultures for 6 to 8 weeks to achieve maximum 
sensitivity on solid Lowenstein Jensen (LJ) media. Liquid culture (BACTEC MGIT 960) is 
the most sensitive culture technique for recovery of mycobacteria from clinical samples 
(103). The liquid culture it’s not currently utilized by all laboratories, particularly in low 
income countries, as a result of limited funding, reduced number of trained and qualified 
personnel and proper biosafety management and equipment. 
 
1.5.1.2.1 Phenotypic identification of the M. tuberculosis complex 
Accurate species identification of the M. tuberculosis complex members is essential, 
particularly in countries with high HIV prevalence, where non-tuberculous mycobacteria 
(NTM) have been identified in human, and M. bovis remains a problem for cattle. 
The traditional methods of species identification is relying on the phenotypic character, which 
is based on biochemical testing including growth characteristics on different media and 
colony morphology. The colony morphology varies among the M. tuberculosis complex 
species ranging from flat smooth, domed glossy colonies to dry and rough colonies. 
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Biochemical tests such as nitrate reductase, detection of niacin, growth in the presence of 
TCH, and catalase activity may be used for differentiation of M. tuberculosis complex species 
(104). All these tests, although simple and inexpensive to perform, require experienced 
personal to interpret the results and do not clearly differentiate between species (105,106). 
 
1.5.1.2.2 Immunochromatographic identification of the M. tuberculosis complex 
The immunochromatographic assays, also called lateral ﬂow assays, have been developed to 
allow differentiation between the M. tuberculosis complex and NTM. It uses a monoclonal 
antibody to detect the MPB64 protein (Rv1980c; also termed as MPT64), which is 
speciﬁcally secreted during growth of M. tuberculosis complex bacteria (107). The 
immunogenic protein MPB64 is highly speciﬁc for M. tuberculosis complex, except some 
variants of M. bovis BCG (108,109) 
Immunochromatographic assays mostly used are commercial kits, including the SD Bioline 
Ag MPT64 Rapid assay (Standard Diagnostics, Kyonggi-do, Korea), Capilia TB (TAUNS, 
Numazu, Japan), and the MGIT TBc Identiﬁcation Test (Becton Dickinson Diagnostic 
Instrument Systems, Sparks, MD).  
 
1.5.1.2.3 Genotypic identification of the M. tuberculosis complex 
In recent years, the identification of NTM has become a challenge for clinical laboratories 
since there are currently more than 150 NTM species catalogued (110). 
Molecular biology techniques have been successfully used for identification of the M. 
tuberculosis complex, with the advantage of being more rapid and accurate than conventional 
methods. 
The introduction of radioisotope-labelled DNA probes and acridinium ester-labelled DNA 
probes (AcuProbes; Gen.Probe) greatly facilitated the identification of commonly isolated 
mycobacteria. Subsequently, commercially available and in-house developed nucleic acid 
amplification tests were successfully used for early identification of M. tuberculosis complex 
grown in liquid cultures.  
Commercially available systems such as the INNO-LiPA (Innogenetics NV, Ghent, Belgium) 
in which the 16S-23S rRNA spacer region of mycobacterial species is amplified and the 
GenoType MTBC (Hain Lifescience GmbH, Nehren, Germany) targeting the 23 rRNA have 
been successfully used to directly detect and identify M. tuberculosis complex. The 
GenoType MTBC, enables rapid differentiation of M. tuberculosis complex bacteria, with 
higher sensitivity compared to the AccuProbe assay (111). 
 
1.5.1.3 Recent diagnostic methods  
Although TB diagnosis in many countries is still reliant on smear microscopy and culture, 
recent techniques are changing the landscape of TB diagnostics, presenting a pipeline of 
various new tools, particularly molecular methods (112). 
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The GeneXpert 
The Cepheid GeneXpert System's MTB/RIF assay is a single use cartridge-based semi-
quantitative nested real-time Polymerase Chain Reaction (PCR) in-vitro diagnostic test that 
detects M. tuberculosis complex DNA and rifampicin resistance associated mutations of the 
RNA polymerase beta (rpoB) gene.   
Based on a WHO meta-analysis of the sensitivity and specificity of Xpert MTB/RIF, the test 
has shown very high sensitivity in sputum samples, 98% in smear-positive, culture positive 
and 79% in people living with HIV. Regarding extrapulmonary  samples, the test shows high 
sensitivity when compared to culture, in diagnosing extrapulmonary  TB from lymph node 
tissues or aspirates (84.9%), gastric lavage (83.8%), cerebrospinal fluid (79.5%) and other 
tissue specimens (81.2%). By contrast pleural fluid samples did not demonstrate good 
sensitivity (43.7%). The specificity is notably high in all groups, more than 92.5% (113). 
Detection of lipoarabinomannan (LAM`) in urine sample 
A number of mycobacterial antigens can be detected in the urine of patients with pulmonary 
TB, but the most promising of these to emerge is the cell wall lipopolysaccharide 
lipoarabinomannan (LAM`) (114–117). 
The commercial test (Allere-Determine TB LAM` in urine) is simple to use, gives rapid 
results, there is no need of instruments and has low cost. The test is sensitive in patients with 
advanced HIV disease but not in HIV negative adults and HIV positive adults with CD4 
counts higher than 100 cells per microliter. (118–121).  
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1.6 STRAIN IDENTIFICATION OF THE M. TUBERCULOSIS COMPLEX 
Genotyping methods are based on the analysis of chromosomal DNA of the M. tuberculosis 
complex. 
A large number of different molecular methods have been developed to measure the genetic 
relationship between different M. tuberculosis complex strains. Ideally, molecular genotyping 
tools should be inexpensive, highly discriminative, deliver rapid results, be straightforward to 
perform, and produce easily and interpretable results that allow for accurate comparison 
between laboratories (122). In order to discriminate between bacterial strains as much as 
possible, the best approach would possibly be whole genome sequencing for each strain. As 
this is at present relatively costly, and require specialized laboratories, only parts of the 
genome are being examined. Each molecular method provides specific genetic profiles 
referred to as fingerprints. When two or more strains have identical fingerprints they are 
referred to as the same cluster and may be epidemiologically linked (123). 
 
1.6.1 Spoligotyping 
Spoligotyping is a simple, rapid, reproducible and cost effective method for simultaneous 
detection and differentiating of the M. tuberculosis complex without the need of purified 
DNA. The method is based on the polymorphism in direct repeat (DR) locus which consists 
of multiple direct variable repeats (DVR). Each DVR is composed of 36 bp-DR and a non-
repetitive short sequence also called spacer (124).  
Spoligotyping can be applied directly to cultured cells and to clinical samples (125).  
The results, expressed as positive or negative for each of the 43 spacers, can be readily 
digitalized. Polymorphism in the DR locus do not discriminate the M. tuberculosis complex 
as well as IS6110 does (i.e., strains with different IS6110 RFLP patterns may have the same 
spoligotype).  
Spoligotypes can be assigned to the major phylogenetic lineages according to signatures 
provided in the international M. tuberculosis molecular markers database, SITVIT2 database, 
of the Pasteur Institute of Guadeloupe  (http://www.pasteur-
guadeloupe.fr:8081/SITVITDemo/?), which is an updated version of the previously released 
SpolDB4 database (57). This database defines 62 genetic lineages/sublineages (57), which 
are often named after regions, countries, cities or places of high prevalence. These include 
specific signatures for the various M. tuberculosis complex members, as well as rules 
defining major lineages/sublineages for M. tuberculosis sensu stricto. 
The various spoligotyping-defined lineages fit well into three large phylogenetical groups: 
ancestral Tuberculosis-specific deletion 1 (TbD1)+/Principal Genetic Group (PGG)1 group 
(East African Indian, EAI), modern TbD1–/PGG1 group (Beijing and Central Asian or CAS), 
and evolutionary recent TbD1–/PGG2/3 group (Haarlem - H, X, S, T, and Latin American 
and Mediterranean or LAM) (126). However, proper epidemiologic and phylogenetic 
inferences are not always an easy task due to a lack of understanding of the mechanisms 
behind the mutations leading to the polymorphism of these genomic targets. It was 
demonstrated that phylogenetically unrelated M. tuberculosis complex strains could be found 
with the same spoligotype pattern as a result of independent mutational events (homoplasy) 
(127), an observation that corroborates the fact that spoligotyping is prone to homoplasy to a 
higher extent than the MIRU-VNTRs (128). Furthermore, spoligotyping has little 
discriminative power for families associated with the absence of large blocks of spacers, e.g., 
the Beijing lineage. 
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1.6.2 IS6110-RFLP 
RFLP was the first standardized molecular typing method. This method is based on the 
detection of the IS6110. The IS6110 is present in different copy numbers and integrated at 
different chromosomal sites in M. tuberculosis complex isolates. The fragments based on 
the IS6110 are highly polymorphic but stable enough for epidemiological studies. Strains 
with fewer copies of IS6110 are more homogenous and the fingerprints are not as reliable 
concerning epidemiological links as of those containing multiple copies (95). 
In this technique, a restriction enzyme, PvuII is used to digest M. tuberculosis DNA and 
southern blots of the DNA electrophoresed on agarose gel are probed with a fragment of 
IS6110 that lies upstream of PvuII site. The RFLP patterns are entered into a computerized 
database and analyzed with an image analysis system. 
 
1.6.3 MIRU-VNTR 
This is a PCR based method that analyses multiple independent loci containing variable 
numbers of tandem repeats (VNTR) of different families of interspersed genetic elements 
collectively called mycobacterial interspersed repetitive units (MIRU) (129). In its original 
format, the PCR primers were each run in separate reactions and the sizes of the products 
were analyzed by gel electrophoresis. 
For the M. tuberculosis complex, the 24-loci MIRU-VNTR is the current reference method 
for surveying transmission events (130,131). A set of 24 MIRU-VNTR loci was standardized 
to increase the discrimination power (131). 
The advantages of MIRU-VNTR analyses are that the results are intrinsically digital and 
analysis can be applied directly to culture without the need for DNA purification. The 
discriminatory power of MIRU-VNTR analysis is typically proportional to the number of loci 
evaluated; in general, when only the 12 loci are used, it is less discriminating relative to 
IS6110 RFLP genotyping for isolates with high-copy-number IS6110 insertions but more 
discriminating than IS6110 RFLP genotyping for isolates with low-copy-number IS6110 
(47). When more than 12 loci are used, or MIRU analysis is combined with spoligotyping, 
the discriminatory power approximates that of IS6110 RFLP analysis (47). MIRU-VNTR 
genotyping has been used in a number of molecular epidemiologic studies, as well as to 
elucidate the phylogenetic relationships of clinical isolates (132–134) and evaluating M. bovis 
transmission (135). 
The standard 24 loci MIRU-VNTR typing lacks resolution power for accurately 
discriminating closely related clones that often compose the Beijing strain populations, thus it 
was proposed a 4 hypervariable MIRU-VNTR loci set as a consensus for subtyping Beijing 
clonal complexes and clusters, after standard typing for epidemiologically relevant subtyping 
in order to ensure transition until whole-genome sequence analysis might become universally 
accessible for TB surveillance (136). 
 
1.6.4 Genomic deletion analysis 
Regions of difference (RD) are used to differentiate between species in the M. tuberculosis 
complex. It is a rapid, simple and reliable PCR-based M. tuberculosis complex typing method 
that makes the use of M. tuberculosis complex chromosomal region-of-difference deletion 
loci. Several specific primers are used to amplify specific loci which together formed a M. 
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tuberculosis complex PCR typing panel (49). The final pattern of amplification products of 
all reactions, given by failure or success, segregates the tested strains from NTM isolates and 
by M. tuberculosis complex subspecies identity. The panel not only provides an advanced 
approach to determine the subspecies of M. tuberculosis complex isolates but also 
differentiate them from clinically important NTM species (49). 
 
1.6.5 Single nucleotide polymorphisms  
Single nucleotide polymorphisms (SNPs) are a common form of genetic variation in M. 
tuberculosis complex. Generally, SNPs represent single nucleotide differences between at 
least two DNA sequences. To generate data on SNP, it requires comparative sequencing of 
multiple genes or whole genomes in two or more strains of interest (137). Thousands of SNPs 
have been discovered in clinical isolates of the M. tuberculosis complex thanks to advances in 
DNA sequencing (138).  
SNPs represent robust markers for inferring phylogenies and for strain classification (139), 
because of the low frequency of SNPs and limited ongoing horizontal gene transfer in the M. 
tuberculosis complex, resulting in low levels of homoplasy (i.e. the independent occurrence 
of the same SNP in phylogenetically unrelated strains) (138,140). In addition, SNPs carry 
functional information, including drug resistance-conferring mutations and can also be used 
to construct transmission networks (141–143). 
 
1.6.6 Whole genome sequencing 
Genome sequencing, generates a complete information of a strain, including the evolutionary 
background, drug resistance mutations, virulence-associated polymorphisms, and assessment 
of TB transmission (144–146), distinguish between relapse and reinfection (147) and 
delineates outbreaks (143).  
Large-scale DNA sequencing studies have usually been performed by specialized sequencing 
centers, but in the upcoming years, it is expected that standard laboratories will be able to 
perform it (148), making it more accessible and affordable. It’s also predicted that whole 
genome sequencing will at least partially replace all previous genotyping methods for the M. 
tuberculosis complex (149).  
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2 THE PRESENT INVESTIGATION 
2.1 STUDY RATIONALE 
Mozambique is one of the high burden TB countries and little information was available 
regarding the genetic diversity of M. tuberculosis complex strains in the country. 
Furthermore, there was no evidence available to define whether bovine TB represents a 
public health problem in Mozambique, especially in HIV infected individuals.  
This thesis describes the molecular epidemiology of the M. tuberculosis complex in 
Mozambique, identifies the predominant genotypes responsible for TB transmission and 
prevalence, and investigates the association between predominant spoligotypes and HIV sero-
status, prevalence and transmission in Mozambique.  
Furthermore, with the aim to determine the occurrence of M. bovis in humans in 
Mozambique, extrapulmonary cases were investigated, including a region where bovine TB 
is a problem in cattle, in order to contribute to a better understanding of the importance of this 
zoonotic disease, what impact it has on the TB epidemic as a whole, and to provide clues on 
how to improve TB control programs with respect to human TB. 
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2.2 OBJECTIVES 
2.2.1 General objective 
- To characterize isolates of the M. tuberculosis complex and estimate the relative 
prevalence of bovine TB in humans in Mozambique. 
 
2.2.2 Specific objectives 
- By molecular genetic methods characterize M. tuberculosis complex isolates into sub-
families and clones. 
- To relate the findings from pulmonary and extrapulmonary  cases. 
- To correlate these findings with the findings in husbandry. 
- To relate the obtained result with international databases and with the results of other 
studies accomplished in neighbouring countries. 
- To study the transmission of TB in HIV co-infected patients in the community by 
assessing the degree of strain clustering. 
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2.3 MATERIAL AND METHODS 
Table 1. Summary of the methods of all papers and study V 
 Main aim Study area Sample size Specimen Diagnostic methods Genotyping methods 
Paper I To identify the predominant 
spoligotypes and lineages responsible 
for pulmonary TB in Mozambique. 
South and North regions 
of Mozambique 
445 Sputum Smear microscopy, ZN 
Culture 
DST 
Spoligotyping 
RD105 
Paper II To investigate the prevalence and 
possible transmission of Beijing strains 
in Mozambique  
Mozambique, all country 543 spoligotyped;  
33 Beijing lineage isolates 
Sputum Smear microscopy, ZN 
Culture 
DST 
Spoligotyping 
MIRU-VNTR 
RFLP 
RD 105, 142, 150, 181 
Paper III To develop a Multiple-locus variable-
number tandem repeat analysis 
(MLVA) based classification of M. 
tuberculosis genotype lineages 
Global 7793 NA NA Spoligotyping 
MIRU-VNTR 
IS6110 insertional events 
Paper IV To characterize the isolates from TBLN  Maputo, capital of 
Mozambique 
110 recruited; 
45 genotyped 
Lymph node fluid ZN cytology 
Culture 
Line Probe Assay 
Spoligotyping 
MIRU-VNTR 
 
Study V  To investigate the transmission of M. 
bovis  
Govuro district, province 
of Inhambane, 
Mozambique 
24 Sputum and lymph 
node fluid 
Smear microscopy, ZN 
Culture 
Spoligotyping 
MIRU-VNTR 
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2.3.1 Study area, patients and samples 
2.3.1.1 Paper I and II 
Study I and II included M. tuberculosis isolates collected during a one year (2007-2008) 
nationwide drug resistance surveillance study performed by the National TB Control Program 
of Mozambique in 40 randomly selected districts around the country. 
A total of 445 isolates from patients older than ≥15 years, new pulmonary TB cases i.e. 
patients with pulmonary TB who had never been treated for TB or had been treated for less 
than 30 days, from seven provinces of Mozambique (Maputo City, Maputo Province, Gaza, 
Inhambane, Nampula, Cabo Delgado and Niassa) were included in study I.  
In paper II, the study was extended to include isolates also from the Central Region of 
Mozambique, with the aim to investigate the prevalence and possible transmission of Beijing 
strains in Mozambique. A total of 543 M. tuberculosis isolates from Mozambique were 
spoligotyped. Of these, 33 belonging to the Beijing lineage, were included. 
In order to compare with Mozambican Beijing strains, 13 previously characterised isolates 
from South Africa representing different Beijing sublineages were included in study II as 
reference strains and genotyped by IS6110-RFLP. To allow comparison with Mozambican 
strains by MIRU-VNTR, 54 previously described isolates from South Africa (122) were also 
included.  
 
2.3.1.2 Paper III 
Study III made use of available genotyping data or in-house typing of six different subsets of 
M. tuberculosis complex clinical isolates encompassing 7793 strains of diverse geographical 
origin as follows: 
1) Spoligotyping and 12-loci MIRU-VNTR data on 7009 strains from the SITVIT2 
proprietary database of Institut Pasteur de la Guadeloupe, n=5990 strains genotyped by 
various investigators, list available through http://www.pasteur-
guadeloupe.fr:8081/SITVIT_ONLINE; n=1019 strains genotyped at Institut Pasteur de la 
Guadeloupe as follows: Guadeloupe n=203; Martinique n=88; French Guiana n=364; 
Dominican Republic n=88; Colombia n=134; and Turkey n=142. 
2) Genotypic data on 176 M. tuberculosis complex isolates from the MIRU-VNTRplus 
database (http://www.miru-vntrplus.org/MIRU/index.faces). The aim of this selection was to 
compare the MLVA based classification of M. tuberculosis complex strains developed during 
this study versus previous labeling using SpolDB4 (57) and Large Sequence Polymorphism 
(LSP)-based classification (139,150). 
3) The MIRU-VNTR rules were further evaluated on a subset of LAM strains to describe the 
novel RDrio lineage (151). This group was subdivided into two subgroups: 100 strains with 
RDrio deletion and 90 wildtype strains. 
4) To test a hypothesis about an Asia-to-Africa back migration theory based on the study of 
Y-chromosome haplogroupsatNeolithictimes (152), published data on 154 M. tuberculosis 
complex strains from the north west of Iran (153) was also used.  
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5) To compensate the lack of MIRU-VNTR data on M. tuberculosis complex isolates from 
East-Africa in all published genotyping databases, 100 strains from Mozambique, from 
study I (154) were typed. 
 
2.3.1.3  Paper IV 
Study IV was conducted from July 2013 to July 2014 at the Pathology Service of Maputo 
Central Hospital. The Pathology Service of Maputo Central Hospital is the only referral site 
in Maputo for diagnosing TBLN, patients suspected of mycobacterial infection are referred 
from different health units for diagnosis. During the study period, they have received 677 
patients suspected of TBLN, of whom, 110 (16.2%) were included in the study. Only patients 
suspected of TBLN that consented and could give at least 0,1ml of sample were recruited to 
participate in the study. That was applied in order to have enough material for the routine 
smear performed in the unit, direct microscopy using conventional ZN staining and cytology, 
and subsequent assays to be performed within the study.  
The swellings observed were cervical, axillary or from other sites, either as a unilateral single 
or multiple mass or masses. Fistula formation could also been seen in certain cases. 
Patients who also had pulmonary involvement were considered as extrapulmonary TB in our 
analysis. 
 
2.3.1.4 Study V 
Study V is still being conducted in the district of Govuro, province of Inhambane, 
Mozambique. Govuro is a region with known high prevalence of bovine TB in cattle. 
Patients ≥18 years, suspected of pulmonary TB or TBLN, from the Donde health center or 
from the community were recruited to participate in the study. The sample collection process 
started in April 2015 and preliminary results of 24 patients are presented. 
 
2.3.2 Sample processing 
Clinical specimens were processed at the individual district laboratories for smear 
microscopy and sputum and sputum or lymph node fluid samples were then referred to the 
National TB Reference Laboratory for further testing.  
Inactivated cultures were sent to the Center of Molecular Biology of Eduardo Mondlane 
University, in Maputo, for molecular characterization and extended analysis was performed 
at the Public Health Agency of Sweden (former Swedish Institute for Communicable 
Disease Control), in Stockholm.  
 
2.3.3 HIV testing 
All patients suspected of having TB were advised and tested voluntarily for HIV/AIDS. The 
patient had a right to refuse HIV testing.   
HIV testing was performed at the Health Unit of enrolment, for patients who consented to 
undergo testing, according to the recommendations by the Ministry of Health of 
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Mozambique. Two rapid HIV tests were used sequentially, Unigold Recombinant HIV 
(Trinity Biotech, Wicklow, Ireland) and Determine HIV-1/2 (Abbot, Tokyo, Japan). Samples 
were tested first with Determine and reported only when negative. Positive samples were 
confirmed with Unigold. All tests were performed and interpreted according to the 
manufacturer’s instructions. 
 
2.3.4 Chromosomal DNA isolation 
Briefly, mycobacteria were harvested, heat killed at 80ºC for 20 minutes and then subjected 
to repeated freeze thawing. Bacteria were resuspended in TE (Tris; EDTA) buffer and lysed 
for two hours at 37ºC. Incubation were made at 65ºC with Sodium Dodecyl Sulphate, 
Proteinase K and finally with Cetyl Trimethyl Ammonium Bromide. A mixture of 
Chloroform-Isoamyl Alcohol was added and DNA was at last precipitated using isopropanol. 
The pellet was centrifuged, washed with 70% ethanol and re-dissolved in TE buffer. 
  
2.3.5 Spoligotyping 
Spoligotyping, previously described in the introduction, was performed to assign all isolates 
to lineages and sublineages. It was performed on genomic DNA according to the manufacture 
instructions (Isogen Bioscience BV, Maarsen, The Netherlands).  
In brief, the DR region was amplified with specific primers and amplified DNA was 
hybridized with a set of 43 spacer oligonucleotides covalently linked to a membrane. A 
hybridization pattern was obtained and subsequently visualized by incubation with 
streptavidin peroxidase (Roche Diagnostics, Germany) followed by detection with Enhanced 
Chemiluminescent Detection system (Amersham Biosciences, UK). Appropriate controls; 
H37Rv, M. bovis BCG, and PCR mixture without DNA were used with each experiment. 
Spoligotyping results were analyzed and dendograms created using the BioNumerics 
Software version 5.01 (Applied Maths, Kortrijk, Belgium) for papers I and II and version 7.5 
(Applied Maths, Kortrijk, Belgium) for paper IV. Spoligotyping patterns were also compared 
with the ones existing in the international Spoligotyping database SITVIT2, which is an 
updated version of SITVITWEB (126).  
 
2.3.6 RFLP 
IS6110 RFLP genotyping, previously described in the introduction, was performed using the 
insertion sequence IS6110 as a probe and PvuII as the restriction enzyme. Visual bands were 
analyzed using the BioNumerics software version 5.01 (Applied Maths, Kortrijk, Belgium). 
Strains with identical RFLP patterns (100% similarity) and five or more hybridizing bands 
were judged to belong to a cluster. On the basis of the molecular sizes of the hybridizing 
fragments and the number of IS6110 copies of each isolate, fingerprint patterns were 
compared by the un-weighted pair-group method of arithmetic averaging using the Jaccard 
coefficient. Dendrograms were constructed to show the degree of relatedness among strains 
according to a previously described algorithm (155) and similarity matrixes were generated to 
visualize the relatedness between the banding patterns of all isolates. 
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2.3.7 RD analysis 
RD analysis was used in paper I and paper II, to investigated five Manu pattern isolates for 
the presence of genomic deletion of RD105 (deleted in the Beijing lineage) and for 
identification of the genomic deletions RD105, RD142, RD150 and RD181 in Beijing 
isolates, respectively. 
The DNA was analyzed by PCR using primers previously described (156). PCR was carried 
out under the following conditions: 10 mM Tris–HCl (pH 8.8), 1.5 mM MgCl2, 50 mM KCl, 
0.1% Triton X-100, 0.5 mM primers, 0.2 mM deoxynucleoside triphosphates, 1U of Taq 
polymerase (Dynazyme) and 10ng DNA per 50ml of reaction mixture. PCR amplification 
was performed under the following conditions: 95°C for 15 min, followed by 35 cycles of 
94°C for 1 min, 62°C for 1 min, and 72°C for 3 min. 10µl aliquots of PCR products were 
analyzed using 2% agarose gel electrophoresis. 
 
2.3.8 MIRU-VNTR 
Standardized 24-locus MIRU-VNTR typing (131) was performed using the MIRU-VNTR 
typing kit (Genoscreen, Lille, France). The PCR-products were run with 1200 LIZ size 
standard (GeneScan, Applied Biosystems) on ABI3131xl sequencers. Sizing of the PCR-
fragments and assignments of MIRU-VNTR alleles were done with the GeneMapper 
software version 4.1 (Applied Biosystems) according to the manufacturers’ instructions. 
 
2.3.9 Phylogenetic analysis 
For paper III, phylogenetic inferences were drawn using two applications: BioNumerics 
(v. 3.5, Applied Maths, Sint-Marteen-Latem, Belgium), and MrBayes3 (available through 
http://mrbayes.csit.fsu.edu/) (157). BioNumerics v. 3.5 (Applied Maths, intMarteen-
Latem,Belgium) was used for phylogenetic reconstruction based on a ‘‘Minimum Spanning 
Tree’’ (MST) algorithm to draw MSTs. For this purpose, allele strings were imported into a 
BioNumerics software package and a MST was created based on categorical and the priority 
rules (http://www.applied-maths.com/bionumerics/plugins/mlva.htm) with highest number of 
single locus variants (SLV’s). MrBayes3 was used to infer phylogeny relationships among 
the newly defined MIRU-VNTR lineages of M. tuberculosis sensu stricto using a bayesian 
approach that is particularly useful to reconfirm MST results (157). 
For paper IV, phylogenetic relationships were calculated using MLVA Compare software v. 
1.03 (Genoscreen and Ridom Bioinformatics). MSTs were drawn from spoligotyping and 24-
loci MIRU-VNTR typing, to better visualize probable relationships and dependencies 
between isolates. 
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2.4 RESULTS AND DISCUSSION 
2.4.1 Paper I 
The primary objective of paper I was to use spoligotyping to characterize isolates from the 
South and North Regions of Mozambique, to assign all the strains in the study to the major 
clades in the SITVIT2 database and to describe the geographical distribution of predominant 
lineages. Additionally, the association between predominant strains and age, HIV status and 
geographical location were investigated. 
In total we studied 445 isolates from new pulmonary TB cases from seven provinces of 
Mozambique. Of these, 282 were from the South region of the country and 163 were from the 
North. Of all patients, 98 (22%) were HIV positive, 122 (27.4%) HIV negative and 225 
(50.6%) were not tested for HIV. 
The predominant lineage was the LAM with 37% of all isolates; followed by the East African 
Indian (EAI), an evolutionary recent T clade, and the globally-emerging Beijing clone 
(Figure 3). The predominance of the LAM lineage was not surprising as it is believed that this 
lineage is globally disseminated, causing about 15% of TB worldwide (158).  
M. tuberculosis genotype distribution of the predominant lineages from the South and North 
regions of Mozambique is illustrated in Figure 3. A comparison of spoligotype distribution 
among the two regions indicates that the LAM, EAI and T lineages were common across the 
country, while the Beijing lineage was found to be more common in the South 27/282 (9.6%) 
compared to the North 4/163 (2.5%). 
 
Figure 3. Geographical distribution of M. tuberculosis predominant spoligotype lineages in 7 provinces of 
Mozambique. The map describes the geographical distribution of predominant spoligotype lineages in Maputo 
city, Maputo province, Gaza, Inhambane, Nampula, Cabo Delgado and Niassa. The number of isolates per 
lineage in each province is depicted.  
When the spoligotyping results and clade definitions were linked to the distribution of clinical 
isolates within PGG 1 versus PGG2/3 (characterized by the lack of spacers 33-36), it was 
evident that 185 or 41.6% of the isolates belonged to PGG1 (ancient lineages) as compared to 
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260 or 58.4% to the PGG2/3 (modern lineages), with a high spoligotype diversity 
documented for EAI, LAM and T lineages (Figure 4). The wide diversity found may be 
attributed to the extensive human movement in the country mainly due to Mozambican 
migration to neighboring countries and internal migration to look for better life conditions, 
since the structure of the TB population is determined by geography, demography and human 
migration. A great part of Mozambican migrants are miners working in South Africa where 
the incidence of HIV among miners is known to be high, varying from 10 to 20% (151); 
Being a mineworker is also considered a risk factor for HIV in Mozambique (159). 
Paper I also attempted to describe the worldwide distribution of predominant Shared 
International Types (SITs) i.e. an identical pattern shared by two or more patients worldwide 
(within this study, or matching another strain in the SITVIT2 database). It was observed that 
many of the predominant SITs were more frequently present in Eastern and Southern Africa 
(mostly among its immediate neighbours Zimbabwe, Zambia, South Africa, Malawi, and to a 
lesser extent to Tanzania, Namibia, and Somalia) (57).  
At the time of this comparison, in the SITVIT2 database no Manu strains were reported from 
Mozambique, and with the exception of three Manu1 lineage strains isolated in Tanzania, all 
the remaining M. tuberculosis Manu strains isolated from Africa belonged to the Manu2 
sublineage. Hence, study I constitutes the first evidence of the presence of the Manu lineage 
in Mozambique. With both Beijing and Euro-American strains (lacking spacers 33-36) 
circulating in Mozambique, some of the Manu2 patterns on the other hand appear to result 
from mixed infections of Beijing and Euro-American TB. Such a mixture has been described 
in adjacent South Africa (134). 
No M. africanum isolates were detected. M. africanum is highly prevalent in West African 
countries, with its epicenter in Guinea Bissau (71,160,161) but is rarely seen in East and 
Southern Africa (162,163).   
The total absence of M. bovis in this one year study is noteworthy. Although bovine TB is an 
important disease of cattle and other domestic animals in Mozambique, no M. bovis, the 
causative agent of bovine TB, was found. One reason could be that only sputum isolates were 
studied. M. bovis is thought to spread through unpasteurized milk, and hence would mainly 
cause abdominal or disseminated TB. Another reason could be that we did not study areas 
with high prevalence of bovine TB in cattle as this information was not accessible at that 
time. In study V, with the aim to evaluate the public health importance of this zoonosis, 
preliminary results from a study performed in a region with known high prevalence of bovine 
TB in cattle are presented. 
M. tuberculosis genotype distribution of the predominant lineages from the South and North 
regions of Mozambique indicates that the LAM, EAI and T lineages were common across the 
country, while the Beijing lineage was found to be more common in the South 27/282 (9.6%) 
compared to the North 4/163 (2.5%). Because of the strong relationship, migration history 
and geographic proximity of Mozambique and South Africa we further investigated the 
Beijing isolates found in this study and compared our findings with the ones from South 
Africa as described in paper II. 
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Figure 4. The principal genetic groups (PGG) in Mozambique. 
A 
     n= 185, 41.% (unknown signature n=6, 1.3%) B 
n= 260, 58.4% (unknown signature n=8, 1.8%) 
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2.4.2 Paper II 
Paper I reported the genotypic lineages of 445 M. tuberculosis isolates collected from the 
North and South regions of Mozambique. The Beijing family was found to be the fourth 
predominant lineage, and the Beijing SIT1 was the third most frequent single spoligotype in 
Mozambique. In study II, we investigated in depth the isolates belonging to the Beijing 
lineage, by extending the study to include isolates also from the Central Region of 
Mozambique, with the aim to investigate the prevalence and possible transmission of Beijing 
strains in Mozambique.  
The Beijing genotype has a worldwide distribution (47,164) and it was reported to be 
associated with HIV infection (165) and MDR-TB (164,166,167). In this study, 14 (10.9%) 
of the 129 HIV positive patients had Beijing strains while 6/141 (4.3%) of HIV negative 
patients had Beijing strains. Thus HIV positive serostatus was significantly (p=0.049) more 
common in patients with Beijing strains than in patients with non-Beijing strains in a 
univariate analysis. In a multivariate analysis (adjusted for age, sex and province) the 
correlation remained significant (p=0.023).The fact that a significant number of patients with 
Beijing strains were HIV positive is worrying. Beijing strains have recently been reported to 
be associated with HIV positive serostatus also in South Africa (165), a connection which is 
further supported here. This association can be due to a combination of increased virulence of 
the strains and an increased susceptibility of HIV infected patients to these strains.  
When we analyzed the association between HIV infection and the other most prevalent 
lineages in the country, an association with HIV was found for the LAM lineage, but for the 
EAI and T lineages no association with HIV was observed, this finding warrants further 
investigation.  
Although Beijing strains have been associated with MDR-TB, only one case was identified in 
this study. 
In relation to the geographic distribution of Beijing strains, we found that the majority of the 
Beijing strains were from the Southern region (n=29), with a prevalence of 10.1% (29/288) 
while in the North the prevalence was 2.4%, (4/164). In the Central region, none of 91 
isolates were of Beijing genotype (Figure 5). In the Southern region we found that, although 
present in the four provinces, the Beijing lineage was most common in Maputo City 16/95 
(16.8%), compared to the other provinces (p<0.001). In a multivariate analysis the correlation 
remained significant between Beijing genotype isolates and Maputo City (p=0.004), 
suggesting that Maputo City and its surroundings is the likely origin.  
Based on spoligotyping, Beijing genotype isolates were identified by the deletion of spacers 
1–34, and the presence of at least three of the nine spacers 35–43 in the DR locus of the M. 
tuberculosis genome.  
Of the 33 strains that were defined by spoligotyping to be of the Beijing genotype, 32 had all 
the characteristic spacers 35-43, corresponding to the shared type SIT1 as defined in 
SITVIT2 (Table 2). One strain (isolate 35) in addition lacked spacer 40, corresponding to 
SIT190.  
Analysis of large sequence polymorphisms has shown that the Beijing lineage has evolved 
into distinct branches defined by specific RD deletions. The large deletion of RD105 is 
considered to be a marker for Beijing strains (156,168,169), although deletion of the RD105 
was also found in ancestral strains with non-Beijing spoligoprofiles (170). From the present 
investigation, 32 of the Beijing genotype strains (31 SIT1 isolates and the SIT190 isolate) 
were analyzed for RD deletions. One isolate was not analyzed because there was insufficient 
  28 
DNA. The majority of the isolates (n=28) had the RD105 and RD181 deletions, while RD150 
and RD142 were intact. Four strains lacked RD105, RD181 and RD150 while RD142 was 
intact (Table 2). 
 
Figure 5. Distribution of Beijing genotype in Mozambique. 
 
By a combined use of RD deletions and spoligotyping the 32 Beijing strains could be 
tentatively divided into three genetic sublineages, A, B and C (Table 2).  
All Beijing genotype isolates (defined by spoligotyping) in this study had the RD105 
deletion. Additional deletions of RD142, RD150 and RD181 may further divide this family 
into different sublineages (156). Interestingly, four out of 32 isolates (sublineage C) lacked 
RD150, a relatively rare deletion, present in a recently evolved sublineage, “sublineage 7”, in 
South Africa, reported to be associated with increased transmissibility and/or pathogenicity 
(168). Moreover the sublineage C isolates were very similar to South African sublineage 7 by 
24-loci MIRU-VNTR and RFLP.  
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Of these four isolates from sublineage C, two (isolates 55 and 327) were from Maputo City 
(male, HIV positive patient and female, unknown HIV status), and one each from Gaza 
Province (female, HIV positive patient) and Cabo Delgado Province (male, unknown HIV 
status). The four patients were all young (20, 33, 20 and 19 years of age).  
 
Table 2. Polymorphisms of M. tuberculosis isolates of Beijing genotype 
  
Spoligotype description Region of difference 
(RD)a 
Genotypic 
sublineage 
Number of 
isolates 
(n=32b) SITc Binary format d 105 142 150 181 
A 27 1 

 − + + − 
B 1 190 

 − + + − 
C 4 1 

 − + − − 
a absence (−) or presence (+) of the specific genomic region 
b RD was not performed in one strain because there was no DNA 
c spoligotype international type, designations were assigned according to the definition in the SITVIT2 
database. 
d The black and white boxes indicate the presence and absence, respectively, of the specific spacer at positions 
1–43 in the DR locus. 
 
IS6110 RFLP and MIRU-VNTR results from Mozambican and South African reference 
strains were analyzed for identification of similarities.  
RFLP was performed on 23 Beijing genotype isolates from Mozambique and 13 Beijing 
reference strains from South Africa. Ten isolates from Mozambique were not analyzed due to 
insufficient DNA. Of the Mozambican Beijing strains, there were four clusters with two 
isolates each as defined by identical IS6110 RFLP patterns (cluster I, II, III and IV). The 
remaining 15 isolates from Mozambique had unique IS6110 RFLP patterns yielding a total of 
19 different patterns. When compared to South African isolates, three additional clusters 
(cluster V, VI and VII) were obtained, each cluster containing one isolate per country (Figure 
6). Cluster V contained isolate 35, the Mozambican SIT190 isolate. Cluster VII contained 
isolate 55 (from a HIV positive patient), one of the sublineage C isolates, which clustered 
with one of the South African “sublineage 7” isolates (Figure 6, marked in red). Isolates 1530 
and 327 (from a HIV positive patient), of sublineage C, were also very similar to the South 
African “sublineage 7” isolates in terms of RFLP pattern. RFLP was not performed on isolate 
46 of sublineage C.    
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Figure 6. IS6110 RFLP dendrogram of Beijing genotype strains from Mozambique and South Africa. 
The dendogram includes 36 M. tuberculosis Beijing genotype strains, 23 from Mozambique and 13 from South 
Africa. Red rectangle indicates sublineage 7 and sublineage C isolates from South Africa and Mozambique 
respectively; Highlighted area shows the clustered isolates from both sublineages. a) Drug resistant isolate; b) 
SIT 190 isolate 
MIRU-VNTR analysis was done on 30 Beijing strains from Mozambique and the obtained 
results were compared with 54 isolates from South Africa previously described (122), each 
one with one unique pattern. The isolates from Mozambique formed seven clusters (2 or 4 
isolates per cluster). Although the Mozambican sublineage C isolates analyzed (55, 327 and 
1530) did not cluster by 24 loci MIRU-VNTR to any of the South African “sublineage 7” 
isolates, they had similar patterns.   
Mozambique and South Africa are neighbouring countries and have a history of cross border 
migration. The fact that four of the Beijing genotype isolates had the RD150 deletion, were 
clustered or were similar by RFLP with South African “sublineage 7” isolates (168), and also 
by MIRU-VNTR were close to the South African “sublineage 7” isolates, and considering the 
high endemicity of this sublineage in South Africa and the low prevalence in Mozambique 
(4/33) suggests that this sublineage could have been recently introduced in Mozambique from 
South Africa.  
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The findings on the low clonality of the strains by MIRU-VNTR and RFLP demonstrate that 
the population structure of the Beijing genotype in Mozambique consists of more than one 
sublineage, indicating that these strains were introduced to the country on separate occasions.  
There are certain limitations of the present study. The study is based on a sample of isolates 
from a drug resistance survey, and may not reflect the true population structure. The low 
number of viable specimens (543 M. tuberculosis isolates from a bank of 1124), and a low 
number of Beijing genotype strains, and the fact that HIV status was not determined for all 
patients and that not all isolates were genotyped by RFLP and MIRU-VNTR are further 
limitations of the study. For this reason further longitudinal studies are recommended, both to 
test the hypothesis that the Beijing genotype is emerging in Mozambique, and to further 
investigate the potential role of HIV infection in this setting.      
 
2.4.3 Paper III 
Considering existing doubts on the ability of spoligotyping alone to reveal exact phylogenetic 
relationships between M. tuberculosis complex strains (128,168), particularly the 
classification of evolutionary recent TbD1–/PGG2/3 group (171); Six different subsets of M. 
tuberculosis complex isolates encompassing 7793 strains were studied. The purpose of this 
paper was to: (i) classify these strains based on 12 locus MIRU-VNTR typing data; (ii) to 
draw the evolutionary history of various M. tuberculosis complex members (species, 
subspecies, groups) leading to the diversity of newly described phylogenetic lineages/groups; 
(iii) to see how the geographical distribution of these lineages reinforces the history of human 
settlement in the world, and finally, (iv) to evaluate the MLVA based classification of M. 
tuberculosis complex genotypic lineages as a means to provide with an accurate and robust 
phylogeographic interpretation of its worldwide diversity. MLVA is useful to establish 
transmission routes and sources of infections for various microorganisms including M. 
tuberculosis complex.  
Phylogenetic inferences were drawn from 12-loci MIRU based MSTs constructed on all the 
7009 M. tuberculosis complex patterns taken from the SITVIT2 database (for which both 
spoligotyping and 12-loci MIRU-VNTR data were available; figure not shown since the 
resulting tree was over-crowded). From this tree, seven major central nodes (or lineages) 
were identified, represented by their respective prototypes: Indo-Oceanic/ MIRU 
International Types - MIRU International Types (MIT) 57, East Asian and African 
Indian/MIT17, Euro American / MIT116, West African-I/MIT934, West African-
II/MIT664, M. bovis/MIT49, M. canettii / MIT60. Further MST subdivision identified an 
additional 34 sublineage MIT prototypes. The phylogenetic relationships among the 37 newly 
defined MIRU-VNTR lineages were inferred using a classification algorithm based on a 
Bayesian approach.  
A MIRU-based MST tree drawn on 176 strains of the MIRU-VNTRplus database (Figure 7) 
showed that the three phylogenetic groups – West African I, West African II and M. bovis are 
phylogenetically close. Considering the fact that the oldest lineages are most distant from the 
Euro American lineage, the tree suggests that West African I and West African II lineage 
strains appeared before M. bovis.  
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Figure 7. MST tree done with 12 MIRU-VNTR loci of 176 strains from MIRU-VNTRplus 
The MIRU-based classification superimposes quite well with that of Brudey for sublineages 
belonging to PGG1, nonetheless discrepancies do exist for PGG2/3 lineages. The classical 
spoligotyping method which uses 43 spacers out of 104 reported spacers in tubercle 
bacilli (172), may not systematically reflect the succession and exact order of spacers on the 
genome. We therefore thought it desirable to have a: (i) finer view of the DR locus using 
extended spoligotyping (57,173), (ii) to detect IS6110 insertions in the DR locus using 
methodology described earlier (169), (iii) use IS6110AD-typing to investigate the role of 
IS6110 insertional event(s) causing deletions in the M. tuberculosis complex genome 
elsewhere than the DR locus. All these three techniques were used on a same set of 100 M. 
tuberculosis complex isolates blindly sampled from an initial set of 445 clinical isolates 
studied in Mozambique (154). The results obtained for selected isolates are summarized 
in Figure 8. 
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Figure 8. Some explanations on the technique of genotyping for the detection of IS6110. 
(A) An illustration for understanding the technique for detection of insertions of IS6110 in the DR locus. (B) 
Result of genotyping of a strain (ID 1172) taken from a sample of 100 Mozambican strains. There are five 
distinct genotyping results with each of the primer sets shown; the 1st line shows the classical spoligotyping 
while the remaining four lines show the detection of IS6110 insertional events as detailed in the text. (C) 
Schematic representation of interpretation of the experiments shown in Figure 8B. Numbers underlined 
correspond to the numbering of the spacers in the 43-spacer spoligotyping format, while those not underlined 
correspond to the numbering of spacers according to their genomic position in the DR locus. The accolades 
mark the points of deletion of spacers. 
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Regarding the demonstration of the IS6110 in the DR locus (Figure 8A), hybridization of a 
spacer by the primer sets (biot)DRa-IS3 or (biot)DRb-IS6 is positive evidence for 
IS6110 insertion in the DR preceding the spacer in question in 5′→3′ direction, while with 
primer sets (biot)DRa-IS6 or (biot)DRb-IS3, it is an evidence for insertion in the direction 
3′→5′. Nonetheless, asymmetrical insertion of IS6110 in the DR can prevent the binding of 
one of the two primers and affect the amplification of the upstream or downstream spacer. 
Hence, we amplified the spacers both on the right and left of the DR repeats to evidence 
IS6110 insertions; indeed these four pairs of primers are expected to produce an amplicon 
containing only a single spacer as shown in Figure 8A. The results obtained for the 86 
extended spacers are summarized for a strain in Figure 8B: 1st line corresponds to use of 
classical spoligotyping primers DRa-Drb, while the 4 other lines correspond respectively to 
primer sets: (biot)DRa-IS3, (biot)DRb-IS6, (biot)DRa-IS6 and (biot)DRb-IS3, and are 
helpful to highlight the presence of IS6110 element(s) in the DR locus. As shown in Figure 
8B, the presence of IS6110 often results in revelation of 1 or 2 adjacent spacers leading to 2 
possible assumptions: (i) either there are several IS6110 inserted into contiguous DR, or (ii) 
part of the amplicon carried by the IS6110 had length variations (since transposable 
elements are known sometimes to carry pieces of genomic sequences; (174).  
Several RDs are reportedly located next to IS6110, e.g., RD152, RD207, RD5, RD11, 
RD14, MiD2 (156,175,176). To determine whether the IS6110was involved in genetic 
recombination that may cause adjacent deletions (177), we applied IS6110 AD-typing to 
selected strains from Mozambique and M. tuberculosis H37Rv. The results obtained 
underlined deletions adjacent to IS6110 insertions. One may postulate that the high 
IS6110 copy number in the H37Rv genome (16 copies) conferred a high mutation rate to 
the DR locus, since the latter is known to be an IS6110 preferential locus. However, 
mechanisms other than IS6110 insertion have been suggested to cause the loss of spacers in 
the DR locus – which is a member of the Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) – such as homologous recombination between DR (178) or 
IS6110 (179), and slippage during DNA replication (180). In a recent study, different 
spoligotypes observed among epidemiologically related strains were attributed to the loss of 
spacer blocks due to recombination between DRs, an event favored by the formation of a 
secondary structure involving two IS6110 in opposite orientation (181), an explanation that 
argues in favor of more complex and interlinked way of M. tuberculosis complex evolution 
involving 2 or more mechanisms simultaneously. In conclusion, insertion sequences 
undoubtedly induce adjacent deletions (177), and no matter the mechanism, the fact that 
IS6110 are observed next to deleted spacers on the DR locus underlines their active 
involvement in DR evolution by loss of spacers. In conclusion, the discrepancies observed 
between spoligotype and MIRU based classification schemes in the cases cited above 
underline that MIRU-based classification tends to group M. tuberculosis complex isolates 
that are phylogenetically close or almost similar albeit they might appear distant if only 
judged based on their spoligotyping patterns.  
The global geographical distribution of the newly defined MIRU-VNTR lineages is 
summarized in Figure 9. The map drawn illustrates the information available in the SITVIT2 
database for the 6800 M. tuberculosis complex isolates recognized as M. tuberculosis sensu 
stricto. The figure shows pie charts with two circles – the inner circle shows the three most 
predominant newly-described lineages, i.e., Indo Oceanic, East Asian and African Indian 
(EAAI), Euro American, whereas the outer circle shows the sublineages belonging to 
uniquely the most predominant of the three lineages (please refer to the color scheme shown 
in the legend to Figure 9). 
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Figure 9. Global geographical distribution of the newly defined MIRU-VNTR lineages. 
To evaluate the ability of 12-loci versus 24-loci MIRU-VNTRs to discriminate M. 
tuberculosis complex sublineages, we constructed two MST phylogenetic trees with 95 
strains of Mozambique (Figure 10), which essentially contained two main lineages – Indo-
Oceanic (42.1%) and Euro American (54.7%). Irrespective of the typing format used (12-loci, 
Figure 10A vs. 24-loci, Figure 10B), none of the trees showed a strong link between these 
two main lineages. Almost the totality of Euro American strains (84.6%) belonged to the 
LAM phylogenetic sub-group B (essentially sublineages Euro American-163 and Euro 
American-128). Regardless of the typing format used, the trees showed the same two big 
clusters (even though the tree made with 24-loci had much more ramifications). We therefore 
conclude that 12-loci format is sufficient to discriminate the present MIRU-VNTR based M. 
tuberculosis complex lineages. 
  36 
 
Figure 10. Two MST phylogenetic trees done with 95 Mozambican strains based on 12-loci MIRU-VNTRs (A), 
and 24-loci MIRU-VNTRs (B). 
The results from the present investigation allowed the construction of an updated 
phylogenetic and phylogeographic snapshot of worldwide M. tuberculosis complex diversity 
studied both at the regional, sub-regional, and country level according to the United Nations 
specifications. We also looked for IS6110 insertional events that are known to modify the 
results of the spoligotyping in specific circumstances, and showed that a fair portion of 
convergence leading to the currently observed bias in phylogenetic classification of strains 
may be traced back to the presence of IS6110. These results shed new light on the 
evolutionary history of the pathogen in relation to the history of peopling and human 
migration. 
 
2.4.4 Paper IV 
In paper IV, we explored the public health risk for bovine TB in Maputo, capital of 
Mozambique, by characterizing the isolates from tuberculous lymphadenitis (TBLN) cases, 
during one year, in the Pathology Service of Maputo Central Hospital. In this study we 
presented for the first time the genetic lineages of M. tuberculosis complex from 
extrapulmonary TB cases from Maputo, Mozambique.  
A total of 110 patients, suspected of having TBLN, were recruited to participate in the study 
(Figure 11). From those patients, 45 isolates were analyzed by genotyping methods, one 
isolate per patient.  
Cervical lymphadenitis was the main cause of TBLN in Maputo. Of the lymph node samples 
39 (86.7%) were collected from the cervical region, two (4.4%) from axillary site and one 
(2.2%) from inguinal region. Other sites were breast, chest and thigh (1 case, 2.2% from each 
site). 
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Among the 45 patients, 30 (66.7%) were HIV positive (19 males and 11 females), nine 
(20.0%) were HIV negative and six (13.3%) were not tested for HIV. Of the cervical TBLN 
cases, 26 (66.7%) were HIV positive patients. No statistical association was found between 
HIV serology and cervical TBLN. Several studies have shown correlation between HIV 
infection and TBLN (182–184). The synergies between TB and HIV infection (185,186) 
have resulted in an increase in the incidence of TBLN and have further complicated TB 
control. In this study, the high prevalence of HIV positive patients (66.7%) among TBLN 
cases, might suggest a rising trend of HIV infection associated with TBLN in Maputo. 
Two patients, EBOV 13-23 (27 years, Lineage T1, SIT53) and EBOV 13-29 (28 years, 
Lineage Beijing, SIT1), both males, HIV positive and not previously treated for TB, were 
diagnosed with MDR-TB (Figure 11).  
Among all, 49 patients had a positive mycobacterial culture, giving a culture positivity rate of 
44.5%. Of them, 48 isolates were identified as M. tuberculosis complex and one as NTM (32 
years, male, HIV positive). From the 59 culture negative patients there were an additional 15 
(25.4%) cases that were ZN positive on cytology (morphological evidence of mycobacterial 
infection). In the remaining 44 patients, based on cytology, there was a specific diagnosis 
other than mycobacterial infection. 
Among the 48 culture confirmed TB cases, 45 isolates were analyzed by spoligotyping and 
MIRU-VNTR. For the remaining three isolates and for the NTM, DNA was not available, 
because there was no growth during the re-culture procedure (Figure 11). 
 
Figure 11. Chart showing patient’s recruitment, culture, identification and resistance results  
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Mixed M. tuberculosis infections is a potential obstacle for TB treatment and control, occurs 
when an individual is simultaneously infected with more than one strain of M. tuberculosis 
complex. In high TB prevalence settings, mixed infections are frequent, implying high 
reinfection rates and the absence of efficient protective immunity conferred by the initial 
infection (134). In patient EBOV 13-19 (male, 59 years, HIV positive), a spoligotype 
SIT2117 (Manu 2; all spacers present except spacers 9, 10, 33 and 43) was observed. This 
type of pattern may correspond to a mixed infection, due to concomitant Beijing and Euro-
American lineage strains (the latter comprising H, LAM, X, and T lineages per spoligotyping 
defined clades). A mixed infection was defined as the occurrence of strains with different 24-
loci MIRU-VNTR patterns at two or more loci in the same sample. We further investigated 
this isolate; by spoligotyping we could observe different intensities of the spacers in the 
spoligotyping pattern (Figure 12) and by MIRU-VNTR we could observe double alleles in 
three different locus (MIRU26, Mtub21, and Mtub30), confirming a mixed infection pattern. 
Since it was confirmed as a mixed infection, the isolate EBOV 13-19 was excluded from 
further genotypic analysis. 
In paper I, we have shown mixed infection with a Beijing and non-Beijing strain in two out of 
five Manu strains from pulmonary TB cases from Mozambique (154). In South Africa, a 
study conducted in Cape Town, showed that 57% of patients infected with a Beijing strain 
were also infected with a non-Beijing strain (134). Other countries have also reported mixed 
infection within different strains from the M. tuberculosis complex, i.e. Botswana (187), 
China (188), Taiwan (189). 
 
Figure 12. Spoligotyping pattern of the strain EBOV 13-19. The picture shows different intensities of the 
spacers 
Spoligotyping was performed on 45 isolates. Of them, all were defined as M. tuberculosis 
and no M. bovis was found. Among the 44 isolates (excluding the mixed infection isolate), 23 
spoligopatterns were obtained. Three patterns corresponded to orphan strains that were 
unique in the SITVIT2 database, as opposed to 20 patterns from 41 patients that 
corresponded to shared-types (SITs), i.e. an identical pattern shared by two or more patients 
worldwide (within this study, or matching another strain in the SITVIT2 database), as shown 
in Table 3. 
For each isolate, their binary/octal description, their lineages and SITs are summarized in 
Table 3. Four SITs (containing seven isolates) were newly created either within the present 
study or after a match with an orphan in the database. Nine patterns were in clusters, 
containing 30 isolates (2 to 6 isolates per cluster), amounting to an overall clustering rate of 
68.2% (30/44). 
As shown in Table 3 the most common spoligotypes found in this study were SIT48 (East 
African-Indian_Somalia; EAI1_SOM) with six isolates; SIT1 (Beijing lineage) and SIT42 
(LAM 9) with five isolates each and SIT53 (T1) with four isolates. The most common lineage 
was the EAI (n=19; 43.2%). 
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Table 3. Shared Types and orphans description in the study, their percentage and lineage within the study. 
SIT* Spoligotype Description Octal code 
Total in 
this 
study 
% in this 
study 
Lineage 
1  000000000003771 5 11.36 Beijing 
42  777777607760771 5 11.36 LAM9 
48  777777777413731 6 13.64 EAI1-SOM 
53  777777777760771 4 9.09 T1 
129  700777747413771 2 4.55 EAI6-BGD1 
806  757777777413731 2 4.55 EAI1-SOM 
4  000000007760771 1 2.27 Unknown 
33  776177607760771 1 2.27 LAM3 
34  776377777760771 1 2.27 S 
60  777777607760731 1 2.27 LAM4 
254  777760007760771 1 2.27 T5-RUS1 
719  776177407760771 1 2.27 LAM3 
952  603777740003771 1 2.27 CAS1-Delhi 
1062  700774007413771 1 2.27 EAI5 
2022  077776775760731 1 2.27 X1 
2915  757737777413731 1 2.27 EAI1-SOM 
4092*  777777717413731 1 2.27 EAI1-SOM 
4093*  457777737413731 2 4.55 EAI1-SOM 
4094*  767777777120771 2 4.55 H3 
4095*  777777477413731 2 4.55 EAI1-SOM 
Orphan**  476000377413771 1 
2.27 EAI5 
Orphan**  742177607760771 1 
2.27 LAM9 
Orphan**  743777777413731 1 2.27 EAI1-SOM 
 
Among the 44 isolates analyzed by MIRU-VNTR, a wide variety of patterns were observed. 
Only three clusters of two isolates each were formed, cluster I (Lineage H3, SIT 4094); 
cluster II (Beijing lineage, SIT 1); cluster III (Lineage EAI1_SOM, SIT 48). The remaining 
patterns were unique, i.e., did not cluster with any other isolate within this study.  
Laboratory detection of bovine TB is a challenge, particularly in low income countries.  
Microscopy for mycobacteria on the Fine Needle Aspiration (FNA) is the initial diagnostic 
procedure for lymphadenitis in Mozambique; although it does not differentiate between M. 
tuberculosis and M. bovis, it is considered a reliable TBLN diagnostic method, including in 
HIV positive individuals (190–193). Molecular typing methods for M. tuberculosis complex 
detection on FNA specimen are costly and require technical expertise, therefore, are not 
implemented as a routine method in the country, making the detection of bovine TB difficult. 
In this study, among all TBLN suspects, 43.6% were confirmed to have M. tuberculosis 
complex strains on culture and one was NTM, no M. bovis was found, showing that M. 
tuberculosis is the main cause of TBLN in Maputo. The additional 15 (25.4%) cases that 
were positive on cytology might be due to infection by either M. tuberculosis complex or 
NTM which were not detected by culture. 
These results are compatible with two studies conducted in the North of Ethiopia, where no 
M. bovis was detected and M. tuberculosis was identified as the main etiological agent in 
TBLN cases (194,195). On the other hand, another study conducted in Guji zone of Ethiopia, 
an area inhabited by pastoral and agro-pastoral communities whose livelihood is based on 
livestock production, among 173 isolates, three were M. bovis; the same study analyzed 39 
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livestock samples, where one M. tuberculosis was isolated in camels, suggesting transmission 
between livestock and humans in this pastoral area. This last study emphasizes the 
importance of an appropriate study area, where risk factors, including close contact between 
humans and livestock, and consumption of raw milk and meat by the communities, are 
present. That can be one of the reasons for the absence of M. bovis in the present study.  
By spoligotyping, the main lineages of TBLN were the EAI, Beijing; LAM and T1; and the 
major SITs, were SIT48, SIT1, SIT42 and SIT53. These genotypes are also predominant in 
pulmonary cases in Mozambique (154), indicating that there are no differences in the 
population of strains in pulmonary and extrapulmonary cases. Similarities between 
pulmonary and extrapulmonary cases were observed in other countries, i.e. Ethiopia (195), 
Thailand (196), Madagascar (197) and Brasil (198). 
In African countries, little is known about the common lineages responsible for 
extrapulmonary TB. A study conducted in the neighboring South Africa, in children, showed 
similarities with our findings, stressing the proximity between the two countries. In the South 
African study, 21.2% of the M. tuberculosis isolates belonged to the LAM lineage, and 20% 
to the Beijing lineages (199). In Uganda, a recent study conducted in lymphadenitis cases, T2 
was the most common lineage (200). In another study performed in Ethiopia, spoligotyping 
revealed that the most common spoligotypes in extrapulmonary TB were SIT54, SIT53, and 
SIT149 (201); SIT54, Lineage T1 was also found to be common in TBLN cases from the 
present study. 
The ancestral EAI lineage, most predominant in this study (42.2%), and one of the prevalent 
lineages in pulmonary TB cases in Mozambique, with a predominance of 29.7% (154); is 
considered to be endemic in the Southern region of India (202,203). The migration link 
between India, particularly South India, and Mozambique arisen since the second half of the 
19th century, when Indian traders practiced the trade routes of the Indian Ocean, for 
transnational connections. The high prevalence of EAI lineages in Maputo might represent an 
indication of TB transmission between the two countries.  
The Beijing lineage was also found to be one of the most common lineages in TBLN cases 
from this study. In South Africa, it was the second most common spoligotype found in 
extrapulmonary cases (199) and in Thailand, Beijing lineage was reported to be the most 
predominant in extrapulmonary TB cases, with 56% (204) and 57.9% (205). Further research 
is needed to evaluate whether Beijing lineage has any particular association with 
extrapulmonary TB. 
We have also shown an association between the Beijing lineage and HIV infection (206), 
although in this study, perhaps because of the sample size, it was not possible to find any 
relationship between a particular lineage and HIV infection. Furthermore, analysis of the 
spoligotyping lineages did not show any association with a particular clinical expression of 
the disease (data not shown). 
Based on MIRU-VNTR analysis, we could observe a wide diversity of patterns, within strain 
lineages, showing that TB lymphadenitis in Maputo is not caused by a particular strain but a 
wide variety of strains, an indication that risk factors for developing TBLN are rather 
associated with host than M. tuberculosis strain. 
In this study, no M. bovis was found. In low income countries there are no effective animal 
TB control programs and surveillance, and the epidemiological and public health aspects of 
infection due to bovine TB are scarce (58,59,61). This situation is aggravated by the presence 
of additional risk factors such as human behavior and the high prevalence of HIV infections 
(58,59,62). In African countries, a median of 2.8% (range 0%–37.7%) of all humans cases of 
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TB are estimated to be caused by M. bovis (61). Variances on prevalence are observed in 
different sites; those differences might be influenced by sampling, study area and diagnostic 
methods. Prevalence varies from; 17% and 4.4% in Ethiopia (207,208), 16% in Tanzania 
(209), 7% in Uganda (210), 3% in Ghana (211) and 15.38 % in Nigeria (212). 
The genotyping findings from this study and the findings in pulmonary cases (154) indicate 
that the overall contribution of M. bovis to human TB in Maputo is minor. However, the 
present study has certain limitations. The small number of positive cases on culture might 
have reduced the chances of finding M. bovis as well as the statistical power and have 
affected the conclusions regarding the significance of the different variables and M. 
tuberculosis lineages. Furthermore, patients from this study are from urban or peri-urban 
areas of Maputo where livestock and consumption of unpasteurized milk is minor, thus, 
exposure to M. bovis is less.  
The occurrence of zoonotic TB is greatly dependent on the presence of bovine TB in cattle. 
M. bovis in cattle is very frequent in certain areas of Mozambique; a recent publication has 
demonstrated a high prevalence of bovine TB in cattle of 39.6% (95% CI 36.8–42.5) in one 
particular district of Mozambique, district of Govuro (213). Another study carried out in 2008 
in the same region reported a bovine TB prevalence rate of 61.9% (95% CI: 55.8–67.8) (214).  
In study V, isolates from the Govuro district were evaluated. 
 
2.4.5 Study V – Preliminary results 
M. bovis in cattle is very frequent in the district of Govuro, located in the province of 
Inhambane, Mozambique. In order to identify the public health importance of bovine TB we 
have characterized mycobacteria isolates from that particular district.  
Preliminary results are based on 24 samples from cases of pulmonary and TBLN suspected 
patients from the Health Center of Govuro and from the community. Basic demographic 
information was collected and spoligotyping and MIRU/VNTR were performed on positive 
cultures in order to identify cases of TB due to M. bovis. 
Among all, 17 were from pulmonary and seven from TBLN suspected cases. Of all, nine 
were culture positive. Of those, six were confirmed as M. tuberculosis complex and three as 
NTM. Spoligotyping and MIRU-VNTR were performed in all M. tuberculosis complex 
isolates and one was confirmed as M. bovis, SB0961. The patient was a female, 40 years, 
HIV positive with TBLN. Interestingly, the same spoligopattern was found in 61% of 178 M. 
bovis isolates from cattle in eight provinces of Mozambique (215).  
The remaining isolates were identified as M. tuberculosis sensu stricto. The NTM isolates are 
still to be identified. 
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3 CONCLUDING REMARKS  
 
Paper I represents the first baseline study of the M. tuberculosis population structure in 
Mozambique, a useful guide for future epidemiological studies in the country and extending 
the picture of global TB distribution. Predominant lineages from Mozambique were also 
found in neighbouring countries and no M. bovis was found in pulmonary cases.  
A particular lineage, the Beijing, was found to be more common in the South 27/282 (9.6%) 
compared to the North 4/163 (2.5%). We further investigated the Beijing isolates with the 
aim to investigate the prevalence and possible transmission of Beijing strains in Mozambique 
and compared our findings with the ones from South Africa (paper II). An association was 
found between HIV positive serostatus and Beijing lineage (p=0.023) and similarities with 
the South African “sublineage 7”, suggesting that this sublineage could have been recently 
introduced in Mozambique from South Africa, in association with HIV infection. 
Based on paper I and paper II findings, my recommendation is to in the near future introduce 
molecular genetic methods at reference level in Mozambique, prioritizing migrant patients, 
with emphasis on mine workers from South Africa in order to identify outbreaks and control 
the transmission between countries, as well as for HIV positive individuals for monitoring 
possible epidemics related to opportunistic strains and drug resistance.  
In paper III, we evaluated the MLVA based classification of M. tuberculosis genotypic 
lineages as a means to provide with an accurate and robust phylogeographic interpretation of 
its worldwide diversity. An updated phylogenetic and phylogeographic snapshot of 
worldwide M. tuberculosis complex diversity was studied both at the regional, sub-regional, 
and country level according to the United Nations specifications. This novel classification 
scheme seems to be a good alternative to support future phylogenetic and epidemiologic 
studies.  
In paper IV, we explored the public health risk for bovine TB in Maputo, by characterizing 
the isolates from TBLN cases. In this study we presented the genetic lineages of M. 
tuberculosis complex from extrapulmonary TB cases from Maputo, Mozambique. No M. 
bovis was found. 
The occurrence of zoonotic TB is greatly dependent on the presence of bovine TB in cattle. A 
study is being conducted presently in the district of Govuro, a region where the prevalence of 
bovine TB in cattle is high, and we have identified the first case of bovine TB in 
Mozambique in that particular area. 
Further investigation is needed on cases of abdominal TB and other forms of TB in Govuro 
and in other pastoral areas, where the prevalence of bovine TB in cattle is known to be high 
in order to have a better answer about the public health importance of this zoonotic disease in 
Mozambique. 
The National TB Control Program in Mozambique should improve on the diagnoses of M. 
bovis as well as encourage collaboration between public health and veterinary public health. 
A ‘one health’ approach can have a positive impact towards the design and implementation of 
appropriate diagnosis, surveillance and prevention of mycobacterial infection, especially in 
areas in which different mycobacteria species are known to be infecting humans and 
livestock. 
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4 REFLECTIONS CONCERNING LEARNING OUTCOMES 
 
In October 2007, I was registered as a licentiate student at the Department of Microbiology, 
Tumour and Cell Biology / Karolinska Institutet during my first visit to the Swedish Institute 
for Infectious Disease Control (presently the Public Health Agency of Sweden). On the 17th 
of June 2011, I defended the licentiate thesis with success at the Karolinska Institutet and in 
August 2012, I was successfully registered as a PhD student at the Department of Clinical 
Sciences and Education / Karolinska Institutet. 
During my PhD studies, I could improve my understanding and gain laboratory skills in 
molecular typing methods, acquired during my stay in Stellenbosch University, in South 
Africa and several visits to the Public Health Agency of Sweden. I could attend several 
postgraduate courses and improve my understanding in different fields, among others, on 
Ethics, Biostatistics, Biosafety, Public Health, basic epidemiology and basic immunology. I 
could also participate in international meetings, several journal clubs and other scientific 
meetings and improve my communication skills and understanding science in different 
contexts. I could also learn how to write science, during these years I had the opportunity to 
write and interact with the journal’s editor in three of the papers from this thesis. 
The sample collection and field work was performed in Mozambique. The sample processing 
and part of the molecular testing was performed at the National TB Reference Laboratory and 
at the Center of Biotechnology of Eduardo Mondlane University. This training allowed 
installation of capacity and training of the laboratory personnel from the National TB 
Reference laboratory in performing spoligotyping.  
The PhD training also had a big impact from the professional point of view. In 2010 I was 
appointed to coordinate the activities of the TB Reference Laboratories in Mozambique and 
in 2014 as the head of the Department of Laboratory Network and Referral Services. Those 
experiences allowed me to learn how to lead a team, interact with different stakeholders and 
somehow participate in the decision making process of TB diagnosis in my country. 
In general, during the past years, I could gain knowledge and systematic understanding of 
TB, and TB molecular epidemiology, be able to carry out scientific analysis and syntheses, 
gain intellectual independence and scientific conscientiousness, gain in-depth insight into 
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